Jump to section
To revolutionize healthcare by delivering patient insights to improve clinical trials.
35% employee growth in 12 months
AiCure leverages artificial intelligence to observe patient behaviour and gain a closer and more scalable understanding of how they respond to various treatments. This is something that the current health system struggles to manage, and results in over 15% of Medicare patients returning to hospital within 6 months of discharge, which ultimately, costs the industry around $25 billion.
AiCure places a large focus on analyzing and encouraging improved patient behaviour and commitment to medication courses. By issuing simple reminders through its patient facing app for patients to take their medication, 90% of users are adhering to their treatment. Their data ingestion and visualization platform documents real time and predictive insights into the efficacy of clinical medical trials and patient care.
The company launched in 2010 with public funding from the National Institute of Health, and has since gone on to raise over $50 million in capital investment input from Palisade Growth Capital, Singtel Innov8 and Silicon Valley Bank, showing that there’s good faith in their offering.
Steph
Company Specialist at Welcome to the Jungle
Jan 2024
$4m
LATE VC
Nov 2019
$24.5m
SERIES C
This company has top investors
Adam Hanina
(Founder)Studied Physics & Economics at Brown, Management at Cambridge, and MBA from Pennsylvania. Managing Director of Biodeo for 4 years. European Business Development at Cerner Corporation for 3 years. Executive Director of European eHealth Forum.